Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | GRM8 | O00222 | 1/20 | 0.65 |
| ▸ | GRM6 | O15303 | 1/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.65 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.65 |
| ▸ | GSR | P00390 | 1/20 | 0.65 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.65 |
| ▸ | GRM5 | P41594 | 1/20 | 0.65 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.65 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.65 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.65 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.65 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.65 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.65 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.65 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.65 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.65 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5813285 | 1.00 | CYP1A2 (0.65) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL17830393 | 1.00 | CYP1A2 (0.65) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL4936629 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL23897855 | 0.86 | ENPEP (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL27675061 | 0.86 | ENPEP (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL11795885 | 0.84 | ALDH1A1 (0.55) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL15797537 | 0.83 | GRM8 (0.86) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL184512 | 0.83 | GRM8 (0.86) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| Glutamic Acid SCHEMBL2803034 | 0.83 | GRM8 (0.86) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| Glutamic Acid SCHEMBL184513 | 0.83 | GRM8 (0.86) | CYP1A2GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114953-A1 | PHYLLOCHLORIN ANALOGUES SUITABLE FOR USE IN PHOTODYNAMIC THERAPY (PDT) | RMW CHO GROUP LIMITED (CN) | 2024-06-06 | — | — | WO | disclosed |
| US-20240067702-A1 | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2023-11-16 | — | — | US | disclosed |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | RA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023137026-A1 | CAMPTOTHECIN ANALOGS CONJUGATED TO A GLUTAMINE RESIDUE IN A PROTEIN, AND THEIR USE | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023094677-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| US-20230144845-A1 | Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11541049-B2 | Tetrahydroisoquinoline derivatives, preparation process and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2009141619-A1 | METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS | Biocant - Associação De Transferência De Tecnologia (PT) | 2009-11-26 | — | — | WO | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| EP-0688314-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021604-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | CYP1A2 50/4885GRM8 4559/4885GRM6 3715/4885 |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | CYP1A2 50/4885GRM8 4559/4885GRM6 3715/4885 |
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | IMMT, MICA, TAP1 | CYP1A2 3232/4885GRM8 3875/4885GRM6 4206/4885 |
| US-20230144845-A1 | Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth | HOGA1, GCDH, LDHB | CYP1A2 2055/4885GRM8 2273/4885GRM6 2004/4885 |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | CYP1A2 3921/4885GRM8 4443/4885GRM6 3431/4885 |
| US-20240067702-A1 | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS | PTMS, PEPD, VIP | CYP1A2 2464/4885GRM8 2012/4885GRM6 1678/4885 |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | CYP1A2 4606/4885GRM8 3786/4885GRM6 4218/4885 |
| US-11541049-B2 | Tetrahydroisoquinoline derivatives, preparation process and use thereof | CYP3A4, CYP3A43, CYP11B2 | CYP1A2 12/4885GRM8 4079/4885GRM6 4663/4885 |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | MRPL38, MRPS27, MRPS18A | CYP1A2 2683/4885GRM8 229/4885GRM6 706/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | CYP1A2 27/4885GRM8 4676/4885GRM6 3316/4885 |
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | CYP1A2 3961/4885GRM8 3528/4885GRM6 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.